Q-omics provides the consensus-scored GIMAP1-GIMAP5 profile across patient tissues and cancer cell-line models. GIMAP1-GIMAP5 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, GIMAP1-GIMAP5 is differentially expressed in 5, with the highest sampling consensus in LUAD. Additionally, GIMAP1-GIMAP5 RNA expression shows 5,451 significant gene co-expression associations, with the highest sampling consensus in SCLC. Together, these results highlight LUSC, LUAD, and SCLC as cancer lineages where GIMAP1-GIMAP5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GIMAP1-GIMAP5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GIMAP1-GIMAP5 survival associations across molecular data types. GIMAP1-GIMAP5 RNA expression shows survival associations in the most cancer types (16), followed by mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GIMAP1-GIMAP5 RNA expression–survival associations across cancer types. High GIMAP1-GIMAP5 expression shows unfavorable associations in LUSC, STAD, LAML, KIRP and DLBC, but favorable associations in KIRC. The LUSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .011). Together, the overview and detailed table identify LUSC as the clearest survival context for GIMAP1-GIMAP5 RNA expression.
This table summarizes GIMAP1-GIMAP5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5, while mass-spec protein shows differences in 3. The strongest signals are observed in LUAD for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for GIMAP1-GIMAP5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GIMAP1-GIMAP5 shows lower tumor expression in LUAD, LUSC, BRCA, KICH and THCA. The LUAD box plot shows higher GIMAP1-GIMAP5 RNA expression in normal versus tumor tissue (log2 FC = −0.020, t-test p < 0.001).
This table shows molecular features associated with GIMAP1-GIMAP5 in patient tissues and cancer cell lines. In patient samples, GIMAP1-GIMAP5 shows the broadest associations at the RNA and protein expression levels, with SCLC recurring as the lineage with the largest associated feature set. In cancer cell lines, GIMAP1-GIMAP5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in SKIN.
